N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Patients who undergo urgent/emergency coronary angiography can not receive any preventive
treatment of contrast induced nephropathy. We tested the hypothesis that Neutrophil
gelatinase-associated lipocalin (NGAL), a new biomarker predictive for AKI, allows early and
effective treatment of contrast induced nephropathy in patients with urgent/emergency
coronary angiography